Novo Nordisk (NVO.N): Adjusted sales for the second quarter of 2026 were DKK 78.49 billion; adjusted operating profit was DKK 33.39 billion. A one-off, non-cash impairment charge of DKK 6.3 billion was incurred in the second quarter of 2026 due to ma

2026-08-05

Novo Nordisk (NVO.N): Adjusted sales for the second quarter of 2026 were DKK 78.49 billion; adjusted operating profit was DKK 33.39 billion. A one-off, non-cash impairment charge of DKK 6.3 billion was incurred in the second quarter of 2026 due to matters related to intangible asset pipeline assets.